Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 15/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | ITK | Q08881 | 1/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23524806 | 1.00 | HCAR2 (0.51) | HCAR2AURKALCKITKRIPK1 | |
| SCHEMBL18366060 | 1.00 | HCAR2 (0.51) | HCAR2AURKALCKITKRIPK1 | |
| SCHEMBL19658997 | 0.87 | ITK (0.48) | HCAR2AURKALCKITKRIPK1 | |
| SCHEMBL23565145 | 0.82 | ITK (0.47) | HCAR2AURKALCKITKRIPK1 | |
| SCHEMBL23567665 | 0.82 | ITK (0.47) | HCAR2AURKALCKITKRIPK1 | |
| SCHEMBL16516777 | 0.78 | HCAR2 (0.52) | HCAR2KMT2ATSHR | |
| SCHEMBL16547215 | 0.78 | HCAR2 (0.52) | HCAR2KMT2ATSHR | |
| SCHEMBL23567958 | 0.75 | ITK (0.40) | AURKALCKITKRIPK1 | |
| SCHEMBL23524790 | 0.74 | HCAR2 (0.49) | HCAR2KMT2ATSHR | |
| SCHEMBL23524992 | 0.74 | HCAR2 (0.49) | HCAR2KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132477-A1 | Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease | PFIZER INC. (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240124439-A1 | Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease | PFIZER INC. (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4263538-A1 | PYRIDO[2,3-D]IMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF ITK FOR THE TEATMENT OF SKIN DISEASE | Pfizer Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230280220-A1 | Benzimidazole Derivative Compounds and Uses Thereof | PFIZER INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11661419-B2 | Benzimidazole derivative compounds and uses thereof | PFIZER INC. (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2022130175-A1 | PYRIDO[2,3-D]IMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF ITK FOR THE TEATMENT OF SKIN DISEASE | PFIZER INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20210188829-A1 | Chemical Compounds | PFIZER INC. (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132477-A1 | Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease | ITK, BLK, BCKDK | HCAR2 2244/4885AURKA 410/4885LCK 170/4885 |
| US-20240124439-A1 | Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease | ITK, PDXK, HRH4 | HCAR2 1608/4885AURKA 339/4885LCK 85/4885 |
| US-11661419-B2 | Benzimidazole derivative compounds and uses thereof | ITK, HRH4, BLK | HCAR2 2282/4885AURKA 349/4885LCK 301/4885 |
| US-20210188829-A1 | Chemical Compounds | ITK, HRH4, HRH1 | HCAR2 1632/4885AURKA 283/4885LCK 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.